ACHIEVE

Completed study

Official Study Title
Anti-inflammatory ClaritHromycin to ImprovE SARS-CoV-2 (COVID-19) infection Early: The ACHIEVE open-label non-randomized clinical trial

Brief Description
ACHIEVE is an open non-randomized clinical trial aiming to prove that the addition of oral clarithromycin to treatment regimen of COVID-19 is associated with early clinical improvement and attenuation of the high inflammatory burden of the host.

Details
Status: Completed
Study Type: Interventional (Clinical Trial)
Study phase: II
Study sites: 4 sites in Greece
Enrolled: 90 participants

ClinicalTrials.gov Identifier: NCT04398004
EudraCT number: 2020-001882-36

Start of trial: May 6th, 2020
End of trial: November 30th, 2020

Condition/Disease studied: COVID-19; Virus Diseases; Corona Virus Infection
Keywords: COVID-19; SARS-CoV-2; Clarithromycin; Hydroxychloroquine

Related publications

• Early Start of Oral Clarithromycin Is Associated with Better Outcome in COVID-19 of Moderate Severity: The ACHIEVE Open-Label Single-Arm Trial
  Infectious Diseases and Therapy 2021 Dec;10(4):2333-2351